Acute dystonia with low-dosage aripiprazole in Tourette's disorder

Annals of Pharmacotherapy

Volumn 40, Issue 4, 2006, Pages 775-777

  Fountoulakis, Konstantinos N ^a,b   Siamouli, Melina ^a   Kantartzis, Sotiris ^a   Panagiotidis, Panagiotis ^a   Iacovides, Apostolos ^a   St Kaprinis, George ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b NONE   (Greece)

Author keywords

Acute dystonia; Aripiprazole; Extrapyramidal symptoms; Tourette's disorder

Indexed keywords

ARIPIPRAZOLE; BENZODIAZEPINE DERIVATIVE; BIPERIDEN; CHOLINERGIC RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT;

ADULT; ARTICLE; CASE REPORT; CLINICAL FEATURE; DYSTONIA; EXTRAPYRAMIDAL SYMPTOM; GILLES DE LA TOURETTE SYNDROME; HUMAN; LOW DRUG DOSE; MALE; MUSCLE SPASM; OCULOGYRIC CRISIS; PRIORITY JOURNAL; PROBABILITY; PSYCHOTHERAPY; SYMPTOM; TORTICOLLIS; TREATMENT OUTCOME;

ACUTE DISEASE; ADOLESCENT; BIPERIDEN; DYSTONIA; HUMANS; MALE; PIPERAZINES; QUINOLONES; TOURETTE SYNDROME; TREATMENT OUTCOME;

EID: 33646271381     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1G331     Document Type: Article

References (20)

1. Apter A, Pauls D, Bleich A, et al. An epidemiological study of Gilles de la Tourette's syndrome in Israel. Arch Gen Psychiatry 1993;50:734-8.
2. Diagnostic and statistical manual of mental disorders. 4th rev. Washington, DC: American Psychiatric Press, 1994.
3. The ICD-10 classification of mental and behavioural disorders-diagnostic criteria for research. Geneva: World Health Organization, 1993.
4. Leckman JF, Zhang H, Vitale A, et al. Course of tic severity in Tourette syndrome: the first two decades. Pediatrics 1998;102:14-9.
5. Ernst M, Zametkin AJ, Jons PH, Matochik JA, Pascualvaca D, Cohen RM. High presynaptic dopaminergic activity in children with Tourette's disorder. J Am Acad Child Adolesc Psychiatry 1999;38:86-94.
6. Sallee FR, Nesbitt L, Jackson C, Sine L, Sethuraman G. Relative efficacy of haloperidol and pimozide in children and adolescents with Tourette's disorder. Am J Psychiatry 1997;154:1057-62.
7. Fountoulakis KN, Iacovides A, Kaprinis GS. Successful treatment with Amisulpride of a woman with Tourette's disorder: a case report. Ann Pharmacother 2004;38:901. DOI 10.1345/aph.1D497
8. Dehning S, Riedel M, Muller N. Aripiprazole in a patient vulnerable to side effects (letter). Am J Psychiatry 2005;162:625.
9. Murphy T, Bengtson M, Soto O, et al. Case series on the use of aripiprazole for Tourette syndrome. Int J Neuropsychopharmacol 2005;8:489-90.
10. Kastrup A, Schlotter W, Plewnia C, Bartels M. Treatment of tics in Tourette syndrome with aripiprazole. J Clin Psychopharmacol 2005;25:94-6.
11. Leckman J, Riddle M, Hardin M, et al. The Yale Global Tic Severity Scale: initial testing of a clinician-rated scale of tic severity. J Am Acad Child Adolesc Psychiatry 1989;28:566-73.
12. McGavin JK, Goa KL. Aripiprazole. CNS Drugs 2002;16:779-86; discussion 787-8.
13. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-45.
14. Schonberger RB, Douglas L, Baum CR. Severe extrapyramidal symptoms in a 3-year-old boy after accidental ingestion of the new antipsychotic drug aripiprazole (letter). Pediatrics 2004;114:1743.
15. Lindsey R, Kaplan D, Koliatsos V, Walters J, Sandson N. Aripiprazole and extrapyramidal symptoms. J Am Acad Child Adolesc Psychiatry 2003;42:1268-9.
16. Lieberman JA. Dopamine partial agonists: a new class of antipsychotic. CNS Drugs 2004;18:251-67.
17. Bowles TM, Levin GM. Aripiprazole: a new atypical antipsychotic drug. Ann Pharmacother 2003:37:687-94. Epub 8 Apr 2003. DOI 10.1345/aph.1C297
18. Grunder G, Carlsson A, Wong DF. Mechanism of new antipsychotic medications: occupancy is not just antagonism. Arch Gen Psychiatry 2003;60:974-7.
19. Marder S. Schizophrenia: somatic treatment. Comprehensive textbook of psychiatry. Philadelpia: Lippincott Williams and Wilkins, 2000.
20. Levine M, Traub S, Burns M. The pharmacology and toxicology of aripiprazole. Internet J Med Toxicol 2004;7:5.